No net renal extraction of homocysteine in fasting humans

被引:123
作者
van Guldener, C
Donker, AJM
Jakobs, C
Teerlink, T
de Meer, K
Stehouwer, CDA
机构
[1] Vrije Univ Amsterdam, Acad Hosp, Dept Nephrol, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Acad Hosp, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Acad Hosp, Dept Clin Chem, NL-1007 MB Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Inst Cardiovasc Res, NL-1007 MB Amsterdam, Netherlands
[5] Univ Childrens Hosp, Utrecht, Netherlands
关键词
amino acids; renal metabolism; chronic renal failure; end-stage renal disease; hyperhomocysteinemia; atherothrombotic risk factor;
D O I
10.1046/j.1523-1755.1998.00983.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. The pathophysiological mechanism of hyperhomocysteinemia in chronic renal failure in humans is unknown. The loss of a putative renal homocysteine extraction in chronic renal failure has been hypothesized as significant homocysteine uptake has been demonstrated in the normal rat kidney. We studied homocysteine extraction in the normal human kidney. Methods. We measured plasma total (free and protein-bound) and free homocysteine (tHcy and fHcy; respectively) in arterial and renal venous blood sampled from the aorta and right-side renal vein during cardiac catheterization in 20 fasting patients with normal renal function. Renal homocysteine extraction was calculated as the arteriovenous difference divided by the arterial level times 100%. Results. No significant renal extraction was demonstrated either for tHcy: 0.9% (SD 5.8; 95% CT -1.8 to +3.6) or for fHcy: -0.2% (11.0; -5.4 to +4.9). Conclusions. We conclude that no significant net renal uptake of homocysteine occurs in fasting humans with normal renal function. The loss of such uptake, therefore, cannot cause hyperhomocysteinemia in patients with renal failure.
引用
收藏
页码:166 / 169
页数:4
相关论文
共 30 条
[1]   The effect of reduced glomerular filtration rate on plasma total homocysteine concentration [J].
Arnadottir, M ;
Hultberg, B ;
NilssonEhle, P ;
Thysell, H .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1996, 56 (01) :41-46
[2]  
ARNADOTTIR M, 1993, CLIN NEPHROL, V40, P236
[3]   Content of sulfur amino acids and vitamin B-6 and related enzyme activities in rats with chronic renal failure fed a high methionine diet [J].
Asagi, K ;
Nakayama, M ;
Kobayashi, M ;
Awata, S ;
Nakayama, K ;
Kodama, H .
NEPHRON, 1996, 74 (01) :175-182
[4]   HEPATIC SULFUR AMINO-ACID-METABOLISM IN RATS WITH CHRONIC-RENAL-FAILURE [J].
BOCOCK, MA ;
ZLOTKIN, SH .
JOURNAL OF NUTRITION, 1990, 120 (07) :691-699
[5]   NET UPTAKE OF PLASMA HOMOCYSTEINE BY THE RAT-KIDNEY IN-VIVO [J].
BOSTOM, A ;
BROSNAN, JT ;
HALL, B ;
NADEAU, MR ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 116 (01) :59-62
[6]   High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients [J].
Bostom, AG ;
Shemin, D ;
Lapane, KL ;
Hume, AL ;
Yoburn, D ;
Nadeau, MR ;
Bendich, A ;
Selhub, J ;
Rosenberg, IH .
KIDNEY INTERNATIONAL, 1996, 49 (01) :147-152
[7]   Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study [J].
Bostom, AG ;
Shemin, D ;
Verhoef, P ;
Nadeau, MR ;
Jacques, PF ;
Selhub, J ;
Dworkin, L ;
Rosenberg, IH .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2554-2558
[8]   Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[9]  
CHAUVEAU P, 1993, KIDNEY INT, V43, pS72
[10]  
CUSWORTH DC, 1968, LANCET, V2, P916